Incyte Hits 52-Week High After Q2 Beat and Raised Guidance
INCY sits 71% above its 52-week low of $69.695 on elevated volume (3.3× avg).
Summary
Incyte shares surged over 9% to a 52-week high of $132.58 following Q2 results that beat expectations and a raised full-year outlook. Revenue jumped 38% to $1.67 billion, driven by strong demand across Jakafi, Opzelura, and other key products. The company lifted 2026 revenue guidance to $5.13–$5.26 billion, reflecting up to 21% growth. This follows yesterday's initial report and adds the market's strong reaction, signaling confidence in the broad-based momentum. With ten data readouts expected in H2 2026, the pipeline remains a key focus.
At the time of this announcement, INCY was trading at $119.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $26B. The 52-week trading range was $69.70 to $132.60. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: dpa-AFX.